Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Cytoplasmic Kaiso is associated with poor prognosis in non-small cell lung cancer

Authors: Shun-Dong Dai, Yan Wang, Yuan Miao, Yue Zhao, Yong Zhang, Gui-Yang Jiang, Peng-Xin Zhang, Zhi-Qiang Yang, En-Hua Wang

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Kaiso has been identified as a new member of the POZ-zinc finger family of transcription factors that are implicated in development and cancer. Although controversy still exists, Kaiso is supposed to be involved in human cancer. However, there is limited information regarding the clinical significance of cytoplasmic/nuclear Kaiso in human lung cancer.

Methods

In this study, immunohistochemical studies were performed on 20 cases of normal lung tissues and 294 cases of non-small cell lung cancer (NSCLC), including 50 cases of paired lymph node metastases and 88 cases with complete follow-up records. Three lung cancer cell lines showing primarily nuclear localization of Kaiso were selected to examine whether roles of Kaiso in cytoplasm and in nucleus are identical. Nuclear Kaiso was down-regulated by shRNA technology or addition a specific Kaiso antibody in these cell lines. The proliferative and invasive abilities were evaluated by MTT and Matrigel invasive assay, transcription of Kaiso's target gene matrilysin was detected by RT-PCR.

Results

Kaiso was primarily expressed in the cytoplasm of lung cancer tissues. Overall positive cytoplasmic expression rate was 63.61% (187/294). The positive cytoplasmic expression of Kaiso was higher in advanced TNM stages (III+IV) of NSCLC, compared to lower stages (I+II) (p = 0.019). A correlation between cytoplasmic Kaiso expression and lymph node metastasis was found (p = 0.003). In 50 paired cases, cytoplasmic expression of Kaiso was 78.0% (41/50) in primary sites and 90.0% (45/50) in lymph node metastases (p = 0.001). The lung cancer-related 5-year survival rate was significantly lower in patients who were cytoplasmic Kaiso-positive (22.22%), compared to those with cytoplasmic Kaiso-negative tumors (64.00%) (p = 0.005). Nuclear Kaiso staining was seen in occasional cases with only a 5.10% (15/294) positive rate and was not associated with any clinicopathological features of NSCLC. Furthermore, after the down-regulation of the nuclear expresses Kaiso in vitro, both proliferative and invasive abilities of three cancer cell lines were significantly enhanced, along with the up-regulation of Kaiso target gene, matrilysin.

Conclusion

Our data suggest cytoplasmic Kaiso expression is associated with poor prognosis of NSCLC and various subcellular localizations of Kaiso may play differential biological roles in NSCLC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Collins T, Stone JR, Williams AJ: All in the family: the BTB/POZ, KRAB, and SCAN domains. Molecular and cellular biology. 2001, 21: 3609-3615. 10.1128/MCB.21.11.3609-3615.2001.CrossRefPubMedPubMedCentral Collins T, Stone JR, Williams AJ: All in the family: the BTB/POZ, KRAB, and SCAN domains. Molecular and cellular biology. 2001, 21: 3609-3615. 10.1128/MCB.21.11.3609-3615.2001.CrossRefPubMedPubMedCentral
2.
go back to reference Daniel JM, Reynolds AB: The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol. 1999, 19 (5): 3614-23.CrossRefPubMedPubMedCentral Daniel JM, Reynolds AB: The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol. 1999, 19 (5): 3614-23.CrossRefPubMedPubMedCentral
3.
go back to reference Spring CM, Kelly KF, O'Kelly I, Graham M, Crawford HC, Daniel JM: The catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-catenin/TCF target gene matrilysin. Experimental cell research. 2005, 305: 253-265. 10.1016/j.yexcr.2005.01.007.CrossRefPubMed Spring CM, Kelly KF, O'Kelly I, Graham M, Crawford HC, Daniel JM: The catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-catenin/TCF target gene matrilysin. Experimental cell research. 2005, 305: 253-265. 10.1016/j.yexcr.2005.01.007.CrossRefPubMed
4.
go back to reference van Roy FM, McCrea PD: A role for Kaiso-p120ctn complexes in cancer?. Nat Rev Cancer. 2005, 5: 956-964. 10.1038/nrc1752.CrossRefPubMed van Roy FM, McCrea PD: A role for Kaiso-p120ctn complexes in cancer?. Nat Rev Cancer. 2005, 5: 956-964. 10.1038/nrc1752.CrossRefPubMed
5.
go back to reference Kim SW, Park JI, Spring CM, Sater AK, Ji H, Otchere AA, Daniel JM, McCrea PD: Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nature cell biology. 2004, 6: 1212-1220. 10.1038/ncb1191.CrossRefPubMed Kim SW, Park JI, Spring CM, Sater AK, Ji H, Otchere AA, Daniel JM, McCrea PD: Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nature cell biology. 2004, 6: 1212-1220. 10.1038/ncb1191.CrossRefPubMed
6.
go back to reference Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FG, Augenlicht LH, Mariadason JM, Hendrich B, Melnick A, Prokhortchouk E, Clarke A, Bird A: Kaiso-deficient mice show resistance to intestinal cancer. Molecular and cellular biology. 2006, 26: 199-208. 10.1128/MCB.26.1.199-208.2006.CrossRefPubMedPubMedCentral Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FG, Augenlicht LH, Mariadason JM, Hendrich B, Melnick A, Prokhortchouk E, Clarke A, Bird A: Kaiso-deficient mice show resistance to intestinal cancer. Molecular and cellular biology. 2006, 26: 199-208. 10.1128/MCB.26.1.199-208.2006.CrossRefPubMedPubMedCentral
7.
go back to reference Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A: Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer research. 2008, 68: 7258-7263. 10.1158/0008-5472.CAN-08-0344.CrossRefPubMed Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A: Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer research. 2008, 68: 7258-7263. 10.1158/0008-5472.CAN-08-0344.CrossRefPubMed
8.
go back to reference Soubry A, van Hengel J, Parthoens E, Colpaert C, Van Marck E, Waltregny D, Reynolds AB, van Roy F: Expression and nuclear location of the transcriptional repressor Kaiso is regulated by the tumor microenvironment. Cancer research. 2005, 65: 2224-2233. 10.1158/0008-5472.CAN-04-2020.CrossRefPubMed Soubry A, van Hengel J, Parthoens E, Colpaert C, Van Marck E, Waltregny D, Reynolds AB, van Roy F: Expression and nuclear location of the transcriptional repressor Kaiso is regulated by the tumor microenvironment. Cancer research. 2005, 65: 2224-2233. 10.1158/0008-5472.CAN-04-2020.CrossRefPubMed
9.
go back to reference Sobin DHWC: International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 2002, New York: Wiley-Liss, 6 Sobin DHWC: International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 2002, New York: Wiley-Liss, 6
10.
go back to reference Travis WDBE, Muller-Hermelink HK, Harris CC: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 2004, Lyon: IARC Press Travis WDBE, Muller-Hermelink HK, Harris CC: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 2004, Lyon: IARC Press
11.
go back to reference Liu Y, Wang Y, Zhang Y, Miao Y, Zhao Y, Zhang PX, Jiang GY, Zhang JY, Han Y, Lin XY, Yang LH, Li QC, Zhao C, Wang EH: Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung cancer (Amsterdam, Netherlands). 2009, 63: 375-382.CrossRef Liu Y, Wang Y, Zhang Y, Miao Y, Zhao Y, Zhang PX, Jiang GY, Zhang JY, Han Y, Lin XY, Yang LH, Li QC, Zhao C, Wang EH: Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung cancer (Amsterdam, Netherlands). 2009, 63: 375-382.CrossRef
12.
go back to reference Wei Q, Zhao Y, Yang ZQ, Dong QZ, Dong XJ, Han Y, Zhao C, Wang EH: Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression. Lung cancer (Amsterdam, Netherlands). 2008, 62: 181-192.CrossRef Wei Q, Zhao Y, Yang ZQ, Dong QZ, Dong XJ, Han Y, Zhao C, Wang EH: Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression. Lung cancer (Amsterdam, Netherlands). 2008, 62: 181-192.CrossRef
13.
go back to reference Zhang S, Guo D, Jiang L, Zhang Q, Qiu X, Wang E: SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC cancer. 2008, 8: 150-10.1186/1471-2407-8-150.CrossRefPubMedPubMedCentral Zhang S, Guo D, Jiang L, Zhang Q, Qiu X, Wang E: SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC cancer. 2008, 8: 150-10.1186/1471-2407-8-150.CrossRefPubMedPubMedCentral
14.
go back to reference Dai SD, Zhang XW, Qi FJ, Xu HT, Wang EH: Expression of E-cadherin, beta-catenin and p120ctn in the pulmonary sclerosing hemangioma. Lung cancer (Amsterdam, Netherlands). 2007, 57: 54-59.CrossRef Dai SD, Zhang XW, Qi FJ, Xu HT, Wang EH: Expression of E-cadherin, beta-catenin and p120ctn in the pulmonary sclerosing hemangioma. Lung cancer (Amsterdam, Netherlands). 2007, 57: 54-59.CrossRef
15.
go back to reference Liu Y, Xu HT, Dai SD, Wei Q, Yuan XM, Wang EH: Reduction of p120(ctn) isoforms 1 and 3 is significantly associated with metastatic progression of human lung cancer. Apmis. 2007, 115: 848-856. 10.1111/j.1600-0463.2007.apm_673.x.CrossRefPubMed Liu Y, Xu HT, Dai SD, Wei Q, Yuan XM, Wang EH: Reduction of p120(ctn) isoforms 1 and 3 is significantly associated with metastatic progression of human lung cancer. Apmis. 2007, 115: 848-856. 10.1111/j.1600-0463.2007.apm_673.x.CrossRefPubMed
16.
go back to reference Xu HT, Wei Q, Liu Y, Yang LH, Dai SD, Han Y, Yu JH, Liu N, Wang EH: Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Annals of surgical oncology. 2007, 14: 3251-3259. 10.1245/s10434-007-9555-9.CrossRefPubMed Xu HT, Wei Q, Liu Y, Yang LH, Dai SD, Han Y, Yu JH, Liu N, Wang EH: Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Annals of surgical oncology. 2007, 14: 3251-3259. 10.1245/s10434-007-9555-9.CrossRefPubMed
17.
go back to reference de la Luna S, Allen KE, Mason SL, La Thangue NB: Integration of a growth-suppressing BTB/POZ domain protein with the DP component of the E2F transcription factor. The EMBO journal. 1999, 18: 212-228. 10.1093/emboj/18.1.212.CrossRefPubMedPubMedCentral de la Luna S, Allen KE, Mason SL, La Thangue NB: Integration of a growth-suppressing BTB/POZ domain protein with the DP component of the E2F transcription factor. The EMBO journal. 1999, 18: 212-228. 10.1093/emboj/18.1.212.CrossRefPubMedPubMedCentral
18.
go back to reference Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D: Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 10762-10767. 10.1073/pnas.94.20.10762.CrossRefPubMedPubMedCentral Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D: Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 10762-10767. 10.1073/pnas.94.20.10762.CrossRefPubMedPubMedCentral
19.
go back to reference Hong SH, David G, Wong CW, Dejean A, Privalsky ML: SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 9028-9033. 10.1073/pnas.94.17.9028.CrossRefPubMedPubMedCentral Hong SH, David G, Wong CW, Dejean A, Privalsky ML: SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 9028-9033. 10.1073/pnas.94.17.9028.CrossRefPubMedPubMedCentral
20.
go back to reference Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP: Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 2005, 433: 278-285. 10.1038/nature03203.CrossRefPubMed Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP: Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 2005, 433: 278-285. 10.1038/nature03203.CrossRefPubMed
21.
go back to reference Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D: The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Molecular and cellular biology. 2002, 22: 4890-4901. 10.1128/MCB.22.13.4890-4901.2002.CrossRefPubMedPubMedCentral Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D: The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Molecular and cellular biology. 2002, 22: 4890-4901. 10.1128/MCB.22.13.4890-4901.2002.CrossRefPubMedPubMedCentral
22.
go back to reference Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB: Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature genetics. 2003, 33: 197-202. 10.1038/ng1077.CrossRefPubMed Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB: Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature genetics. 2003, 33: 197-202. 10.1038/ng1077.CrossRefPubMed
23.
go back to reference Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005, 123: 437-448. 10.1016/j.cell.2005.08.011.CrossRefPubMed Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005, 123: 437-448. 10.1016/j.cell.2005.08.011.CrossRefPubMed
24.
go back to reference Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K, Barton MC, Deroo T, Vleminckx K, Moon RT, McCrea PD: Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Dev Cell. 2005, 8: 843-854. 10.1016/j.devcel.2005.04.010.CrossRefPubMed Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K, Barton MC, Deroo T, Vleminckx K, Moon RT, McCrea PD: Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Dev Cell. 2005, 8: 843-854. 10.1016/j.devcel.2005.04.010.CrossRefPubMed
25.
go back to reference Ogden SR, Wroblewski LE, Weydig C, Romero-Gallo J, O'Brien DP, Israel DA, Krishna US, Fingleton B, Reynolds AB, Wessler S, Peek RM: p120 and Kaiso Regulate Helicobacter pylori-induced Expression of Matrix Metalloproteinase-7. Molecular biology of the cell. 2008, 19: 4110-4121. 10.1091/mbc.E08-03-0283.CrossRefPubMedPubMedCentral Ogden SR, Wroblewski LE, Weydig C, Romero-Gallo J, O'Brien DP, Israel DA, Krishna US, Fingleton B, Reynolds AB, Wessler S, Peek RM: p120 and Kaiso Regulate Helicobacter pylori-induced Expression of Matrix Metalloproteinase-7. Molecular biology of the cell. 2008, 19: 4110-4121. 10.1091/mbc.E08-03-0283.CrossRefPubMedPubMedCentral
Metadata
Title
Cytoplasmic Kaiso is associated with poor prognosis in non-small cell lung cancer
Authors
Shun-Dong Dai
Yan Wang
Yuan Miao
Yue Zhao
Yong Zhang
Gui-Yang Jiang
Peng-Xin Zhang
Zhi-Qiang Yang
En-Hua Wang
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-178

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine